US FDA’s Remote Assessments Pose Risks For Drug Manufacturers
Executive Summary
Information shared through a remote interactive evaluation or records request could create 'fact traps' for companies during subsequent discussions with the agency, and there’s a chance the data could be misunderstood; also, it remains to be seen if findings from remote evaluations could support civil or criminal proceedings, lawyers and consultants tell a FDLI conference.